发明授权
- 专利标题： 1,4 oxazines as BACE1 and/or BACE2 inhibitors
- 专利标题（中）： 1,4个恶嗪作为BACE1和/或BACE2抑制剂
-
申请号： US13348675申请日： 2012-01-12
-
公开(公告)号： US09242943B2公开(公告)日： 2016-01-26
- 发明人: Matteo Andreini , Emanuele Gabellieri , Wolfgang Guba , Hans Hilpert , Alexander V. Mayweg , Robert Narquizian , Eoin Power , Massimiliano Travagli , Thomas Woltering , Wolfgang Wostl , Harald Mauser
- 申请人： Matteo Andreini , Emanuele Gabellieri , Wolfgang Guba , Hans Hilpert , Alexander V. Mayweg , Robert Narquizian , Eoin Power , Massimiliano Travagli , Thomas Woltering , Wolfgang Wostl , Harald Mauser
- 申请人地址： IT Siena US NJ Nutley
- 专利权人： SIENA BIOTECH S.P.A.,HOFFMANN-LA ROCHE INC.
- 当前专利权人： SIENA BIOTECH S.P.A.,HOFFMANN-LA ROCHE INC.
- 当前专利权人地址： IT Siena US NJ Nutley
- 优先权： EP11151294 20110118
- 主分类号： C07D265/30
- IPC分类号： C07D265/30 ; C07D413/12 ; A61K31/5375 ; A61K31/5377 ; A61P25/28
摘要：
The present invention relates to 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
公开/授权文献
- US20120184540A1 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS 公开/授权日：2012-07-19
信息查询
